RESEARCH ARTICLE

Psychosocial Care Needs of Melanoma Survivors: Are They Being Met?

Sabine Fischbeck1,*, Barbara H. Imruck2, Maria Blettner3, Veronika Weyer3, Harald Binder3, Sylke R. Zeissig4, Katharina Emrich4, Peter Friedrich-Mai2, Manfred E. Beutel2

1 Department of Psychosomatic Medicine and Psychotherapy, Medical Psychology and Medical Sociology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, 2 Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, 3 Institute for Medical Biometrics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, 4 Institute for Medical Biometrics, Epidemiology and Informatics (IMBEI), Cancer Registry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

* fischbec@uni-mainz.de

Abstract

Patients who have survived malignant melanoma for more than five years may lack the opportunity to talk about their burden. As a consequence their psychosocial care needs remain undetected and available supportive interventions may not be utilised. Therefore, the psychosocial burden of this patient group needs to be assessed using specific screening instruments. The aim of this study was to investigate the psychosocial burden of long-term melanoma survivors, their psychosocial care needs and the determinants of these needs. We wanted to find out if the use of professional support corresponds to the care needs defined by experts. Using the cancer registry of Rhineland-Palatinate, melanoma patients diagnosed at least 5 years before the survey were contacted by physicians. N = 689 former patients completed the Hornheide Questionnaire (short form HQ-S) to identify psychosocial support need (scale cut off ≥ 16 or item-based cut-off score) and the potential psychosocial determinants of these needs. Additionally, they were asked about their utilisation of the professional support system. More than one third (36%) of them was in need for professional psychosocial support. The highest burden scores concerned worry about tumour progression. Younger age (< 50), higher general fatigue, higher symptom burden, lower general health, negative social interactions and unfulfilled information needs were significant predictors of the need for psychosocial intervention. Related to the percentage of survivors identified as ‘in need’, the professional support system was underused. Further studies should investigate whether using the HQ-S to routinely identify burdened melanoma patients could lead to better fulfilment of their intervention needs, ultimately enhancing health-related quality of life.
Introduction

According to latest information from the German Cancer Registration in 2010, 19,220 people were diagnosed with malignant melanoma in Germany, 9,640 women and 9,580 men. Therefore, malignant melanoma accounted for 4.3% and 3.8% of malignant tumours in women and men, respectively [1]. Since the 1980s the incidence rate has tripled. This can be explained by changes in leisure time behaviour of light-skinned people and increasing solar exposition of the skin [2]. In view of this malignant melanoma shows the most precipitous increase of a preventative carcinoma and the most frequent cancer in middle-aged adults [2].

The success of treatment is highly dependent on the tumour staging. Approximately 90% of malignant melanomas are diagnosed as a primary tumour without detectable metastases (stage I or II). Therefore, the 10-year survival rate of 75% to 80% is comparatively good. The median survival of patients with a metastatic carcinoma (stage IV), however, is only 6 to 7 months [3]. Depending on tumour localisation, surgical intervention can cause severe disfigurements, especially in the head and neck area [4]. Tumour progression remains an on-going threat for the survivors. Within 10 years, this occurs in approximately 6–14% of cases, including cases of early stage carcinomas and after successful primary treatment [4].

Patients treated for melanoma should receive life-long aftercare. Clinical guidelines recommend regular follow-ups, consisting of a full body skin examination by a physician, complemented by regular patient or partner-assisted self-examination [5]. However, internationally there is poor consensus regarding medical and psychosocial follow-up care [6]. The guidelines of the German Society of Dermatology and the German Cancer Societies recommend an aftercare regimen of more than 10 years, including psycho-oncological care. Whereas the medical aftercare is specified, there are no clear recommendations for psychosocial screening or interventions, with the exception of the recommendation that patients at risk should be referred for professional psychosocial support [7]. Little is known about if and how medical and psychosocial follow-up care are used by long-term survivors of malignant melanoma. A systematic literature review [8] found only 31 empirical psycho-oncological studies of malignant melanoma since 1990, and most were methodically weak. Data on psychosocial care needs were very inconsistent.

In a systematic review of published studies, Kasparian et al. [9] found that approximately 30% of all patients diagnosed with melanoma, including long-term survivors, reported levels of psychological distress indicative of the need for clinical intervention. Based on the Hornheide Questionnaire, a need for psychosocial intervention has been identified in 45% melanoma patients out of a sample (n = 846) of patients with skin and head tumours. This prevalence was higher than in samples of squamous cell carcinoma (39%) and basalioma (34%) patients. Fear of recurrence, lack of professional support, distress, nervousness, job-related stress, reduced self-confidence and subjective well-being were the main reasons for being in need of intervention [10]. As Winzer et al. [11] pointed out, cancer patients’ perceived (self-assessed) need for psychosocial support may be different from the assessment of the health care professionals. Also, an individual who expresses a need for support may not necessarily access help. They did not find any relation between subjective and normative need, but the data partly rely on a very small sample; only 9% of melanoma patients identified a need for psychosocial intervention.

According to Schulz et al. [12] patient use of intervention options can be conceptualised as a complex multistep decision procedure, from the perception of a problem to the individual decision to access professional help. Based on different cancer entities, a number of studies have identified social and clinical variables as predictors of psychosocial intervention needs. The need was more pronounced when the illness was advanced or metastatic [13, 14, 15, 16], e.g. tumour size greater than 4 mm, affecting the head and neck area and diagnosed less than 3
years ago [13]. Cancer patients were more likely to need support when they were female [13, 17, 18], of younger age [13, 17], belonged to a higher social class [17], were without a partner [13] and were less educated [14]. Insufficient physician support [15], low social support [15] and detrimental interactions with others [14] were also determinants of care needs. High symptom burden, low quality of life [14], fatigue [17], an avoidant [17] or depressive coping style [19, 20] were additionally associated with a need for care. The same was true for fear of progression [15, 19, 20], higher psychosocial burden, comorbid depression or anxiety and the feeling of being insufficiently informed about the illness and supportive institutions [19, 20].

Self-assessments of melanoma patients regarding their burden differed from the assessments of their physicians [21]. Care needs can be underestimated and remain unmet, so a systematically psychometric screening is necessary to prevent this. Indeed, many melanoma patients desired additional consultations with a physician (59%) or a psychotherapist (20%), indicating that their needs for care had not been recognized [19]. As we could show recently, distress ratings of melanoma patients (a total of 47%; [22]) by far exceeded distress identified by physicians (in 7%; [23]); thus, it can be surmised that care needs are underestimated and remain unmet. Thus, a systematical psychometric screening may be required in order to detect patients’ need for care.

The purpose of MeLa, a cross-sectional registry-based study, was to determine the prevalence of burden and need for psychosocial support of melanoma survivors. The study examined predictors of psychosocial intervention needs, taking into account illness characteristics, demographic data, health-related quality of life, fatigue, coping with illness, social support, comorbidity of depression and anxiety disorder and information needs. We also investigated whether the need for psychosocial intervention based on a standardised scale is associated with the utilisation of the psychosocial health care system. We assumed that psychosocial care was underused compared with needs identified. We further that patients with high psychosocial burdens use the professional support system more often than the patients under the cut-off score.

Patients and Methods

Study design and participants

All patients with a diagnosis of malignant melanoma (ICD-10: C43) who had been registered by their dermatologist (n = 112) with the Cancer Registry of Rhineland-Palatinate as part of routine documentation were eligible. Inclusion criteria were a) registration in the time period from 2000 to 2005, b) age of 14 years or older at diagnosis and signed written informed consent for study participation. We excluded those patients a) who were not informed about their registration and b) did not have adequate German language comprehension or cognitive ability to participate. For legal reasons and in order to insure confidentiality, only the Cancer Registry was allowed to decode the name of the patient. Only the dermatologist who had originally registered the patient was eligible to contact the patient, who was then provided with a written informed consent form and the questionnaire. Patients who did not react to the letter within six weeks received a reminder letter and were contacted once more. Those who still did not respond were not contacted further. Data analysis was performed with coded data without reference to any personal identification.

Two thirds (67%) of the dermatologists took part. They requested questionnaires for n = 1702 patients, representing 80.5% of all eligible patients (n = 2113). Of all contacted patients (n = 1320), n = 689 questionnaires were returned. Thus, 52.2% of the contacted patients took part, representing 32.6% of registered patients. We could not reach 19.4% of the patients because the corresponding dermatologists were not reachable.
Ethics statement

The protocol was approved by the Ethics Committee of the Statutory Physician Board of the State of Rhineland Palatinate (Reference number 837.161.11, 7703).

Measures

Sociodemographic data were obtained using a standardised self-reporting questionnaire. Illness-related information (UICC stage, tumour site, time since diagnosis) was extracted from the Rhineland-Palatinate Cancer Registry.

Psychosocial care needs were assessed by using the 9 Item Short Form of the Hornheide Questionnaire (HQ-S) [24], including physical and mental wellbeing, tumour-related anxiety, tension, self-esteem, social support, physician support and the information needs of skin cancer patients. This reliable measure (Cronbach’s $\alpha = .87$ in the MeLa data set) has been developed for skin cancer patients and has shown good validity [25, 26]. The questionnaire allows for the identification and classification of patients in need of professional psychosocial or psycho-oncologic intervention. The degree of the distress is measured on a scale from 0 "does not apply" to 5 = "applies and troubles me extremely". Item cut-off scores for each distress dimension and a cut-off score for the scale sum ($\geq 16$) were developed by the author of the test and validated by clinical interviews in order to classify the need for psychosocial intervention.

Depression was measured using the German version of the Patient Health Questionnaire Depression Module (PHQ-9 [27]; Cronbach’s $\alpha = .86$ in the MeLa data set). Categorisation of depression is defined as a score of PHQ-9 $\geq 10$, indicating moderate to severe depressive symptoms for the past two weeks [28]. Sensitivity is 92% for major depression (cut-off $\geq 10$) in primary care, while specificity is somewhat lower (80%) [29].

The Generalized Anxiety Disorder Questionnaire (GAD-7) of the PHQ was used to identify probable cases of generalised anxiety disorder and to assess symptom severity. The GAD-7 is based on the most prominent diagnostic features of the DSM-IV diagnostic criteria for generalised anxiety disorder. Seven items are scored on a four-point Likert scale over the past two weeks from 0 (“not at all”) to 3 (“nearly every day”), with a total score ranging from 0 to 21. Reliability, validity and standard scores were established by using a representative German population sample ($n = 5036$; age $48 \pm 18$ years, 54% female [30]. Internal consistency in the MeLa data set is Cronbach’s $\alpha = .89$. The EORTC Quality of Life Core Questionnaire EORTC-QLQ-C30 [31] measures cancer-related quality of life reliably and with good validity using five functional scales (physical, role, cognitive, emotional, social; in the MeLa data, Cronbach’s $\alpha = .80/.90/.68/.89/.85$ in order of the previous list), three symptom scales (pain, fatigue, nausea/vomiting; in the MeLa data set Cronbach’s $\alpha = .89/.85/.33$), a global health and quality of life scale, and six single items assessing additional symptoms commonly reported by patients (e.g. appetite loss, sleep disturbance) as well as the perceived financial impact of the disease and treatment. The EORTC QLQ-C30 consists of 30 items that are scored on 4-point Likert scales, ranging from 1 (“not at all”) to 4 (“very much”). Two items in the global health and quality-of-life subscale are scored on a 7-point linear analogue scale. All functional scales and individual item scores are transformed to a 0–100 scale.

Fatigue was assessed using the Multidimensional Fatigue Inventory (MFI), an internationally validated, multidimensional self-administered instrument [32]. Its 20 items form the following subscales (Cronbach $\alpha$ in the MeLa data set in parentheses): General ($\alpha = .81$) physical ($\alpha = .86$), and mental fatigue ($\alpha = .81$), reduced motivation ($\alpha = .65$), and reduced activity ($\alpha = .84$). Each subscale contains four items (range from 4 to 20, with higher scores indicating increased fatigue). The German version shows moderate to good reliability Convergent validity was moderate for aspects of quality of life [33].
The 24-item German version of the Illness-specific Social Support Scale (ISSS) measures emotional, informational and practical support [34]. The two scales “positive social support” (15 items) and “detrimental interaction” (9 items) are scored on a 5-point Likert scale ranging from 0 (“never”) to 4 (“always”). The authors report a high reliability and good factorial validity. Internal consistency in the MeLa data set is Cronbach’s α = .94 for the positive social support scale and .72 for the detrimental interactions scale. Construct validity is supported by positive correlations to selected variables of social interaction.

The Brief Cope (BC) is a short version of the COPE questionnaire [35, 36], which has proven useful in health-related research. It consists of 14 coping scales with a Likert scale (1 = “never” until 4 = “very often”), each with two items (e.g. “self-distraction”, “active coping”, “denial”, “substance use” and “use of emotional support”). Due to the fact that more than half of the scales have a Cronbach Alpha coefficient under .70, we decided to perform a cross validation in our sample. An exploratory factor analysis with the Brief Cope items led to three interpretable coping scales with acceptable reliability (accounting for 38% of total variance). The first dimension could be labelled as “seeking external support” (α = .75), the second “denial/self-blaming” (α = .74), and the third “active coping” (α = .76). The dimensions are in good accordance with other Brief-Cope-related analytic results [37, 38].

**Service and information needs**

Since there were no standardised scales for measuring service and information needs for melanoma patients, we developed nine dichotomised single questions (“yes/no”) addressing main domains [14, 19] of support sources (psychological counselling, social counselling, pastoral care, self-help group, cancer care counselling, telephone counselling, internet counselling, internet forum with concerned persons). For measuring information needs we did not find a suitable standardised questionnaire and developed an ad hoc scale with 15 illness, therapy or psychosocial care related items covering main aspects: diagnosis, chance of recovery, course of the disease, treatment, side effects, other therapy options, course of the therapy, follow-up care, genetic risk, prevention, rehabilitation, psychosocial support, self-help groups, participation in studies, and a second opinion. Patients rated on Likert scales with five steps (1 = “not at all” to 5 = “very much”) about how adequately they felt informed about the issues. Ratings were dichotomised (0 = rather/much informed: no information deficit; 1 = not at all/little/a bit informed: information deficit) to determine the percentage of patients with an information deficit.

**Statistical analysis**

For descriptive analysis, absolute and relative frequencies were computed for the categorical variables. Missing data were replaced according to the recommendations of the test authors. Associations between the standardised questionnaires were determined using Spearman’s correlation coefficients in order to determine the validity of the HQ-S. For the categorisation of ‘being in need’ of psychosocial intervention, the HQ-S item cut-off score and the sum score cut-off (calculated from the item scores) were used. Social class was determined using a common index [39]. In order to estimate the effects of the socio-demographic data (gender, age, marital status, education, social class, urban/rural destination), social variables (partnership/the medical issues (UICC status, time since diagnosis), comorbidity (PHQ-9, GAD-7) and psychosocial variables (scales of the MFI, Brief COPE, ISSS; EORTC-Symptoms, EORTC-Global Health) on the care needs (HQ-S), a logistic regression model was fitted. We present adjusted odds ratios, the corresponding 95% confidence intervals and p-values. Because of missing values in the potential predictors, a multiple imputation was performed [40]. We used a multiple
Table 1. Demographic and medical characteristics of the sample (n = 689).

| Age      | n   | %   |
|----------|-----|-----|
| < 39     | 52  | 7.6 |
| 40–49    | 111 | 16.1|
| 50–59    | 137 | 19.9|
| 60–69    | 133 | 19.3|
| 70–79    | 184 | 26.7|
| ≥ 80     | 72  | 10.5|

| Gender: male | n   | %   |
|--------------|-----|-----|
|              | 335 | 48.6|

| Marital status        | n   | %   |
|-----------------------|-----|-----|
| Single                | 49  | 7.1 |
| Married               | 520 | 75.5|
| Separated/divorced    | 49  | 7.1 |
| Widowed               | 70  | 10.2|

| Partnership: yes | n   | %   |
|------------------|-----|-----|
|                  | 570 | 82.7|

| Educational level  | n   | %   |
|--------------------|-----|-----|
| Primary school     | 333 | 48.3|
| Secondary school   | 196 | 28.4|
| High School        | 142 | 20.6|
| Other              | 17  | 2.5 |

| Residence: rural | n   | %   |
|------------------|-----|-----|
|                  | 496 | 72.0|

| Time since diagnosis (years) | n   | %   |
|------------------------------|-----|-----|
| 6                            | 104 | 15.1|
| 7                            | 139 | 20.2|
| 8                            | 129 | 18.7|
| 9                            | 107 | 15.5|
| 10                           | 96  | 13.8|
| 11                           | 88  | 12.9|
| 12                           | 26  | 3.8 |

| Social class | n   | %   |
|--------------|-----|-----|
| Lower        | 237 | 34.4|
| Middle       | 234 | 34.0|
| Higher       | 218 | 31.6|

| UICC stage at diagnosis | n   | %   |
|-------------------------|-----|-----|
| 1                       | 365 | 53.0|
| 2                       | 34  | 4.9 |
| 3                       | 7   | 1.0 |
| Unknown                 | 283 | 41.1|

| Melanoma surgery: yes | n   | %   |
|-----------------------|-----|-----|
|                       | 660 | 97.1|

| Tumour site ICD-10 (malignant melanoma) | n   | %   |
|----------------------------------------|-----|-----|
| extremities (C43.6, C43.7)             | 329 | 47.7|
| trunk (C43.5)                          | 248 | 36.0|
| head and neck (C43.2-C43.4)            | 93  | 12.5|
| overlapping skin/not otherwise specified (C43.8, C43.9) | 19  | 2.8 |

\(^1\)UICC-stage: till 2003 (year of diagnosis) according to TNM 5. ed., Springer publisher 1997, from 2004 (year of diagnosis) TNM 6. ed., Springer publisher 2002; classification according to TNM 6 in A and B were subsumed to the particular stage; missing data: marital status (1), partnership (23), educational level (1), melanoma surgery (9)

doi:10.1371/journal.pone.0132754.t001
imputation with k = 10 imputed data sets via the SAS procedure MI. For two randomly chosen single imputation data sets, we selected a set of covariates with a logistic regression model using forward and backward selection with a selection level of 5%.

For each single imputation data set, we then performed logistic regression models for the previously selected covariates and combined the results via the SAS procedure MIANALYZE. This logistic regression model was used for confirmatory analyses.

Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA, version 21.0) and SAS 9.2 for Windows 9.2 TS Level 1M0 (SAS Institute Inc. Cary, NC, USA).

Results
Sample
Our sample included 689 malignant melanoma survivors (354 women and 335 men; see Table 1). Nearly two thirds of the participants were 50 years old or older. Most were diagnosed at stage UICC 1 (no spread or distant sites, 53%) and the melanoma was located in the extremities (47.7%); 97.1% had melanoma surgery. At the time of the study, 69.5% had lived with their illness for 6 to 9 years, 31.5% 10 years or more. Most were married (75.5%), 82.7% had a partner and lived in rural communities (72%). Regarding education, 48.3% had attended primary, 28.4% secondary and 20.6% senior high school. Social class was equally distributed among lower (34, 4%), middle (34%) and upper social class (31.6%)

Need for psychosocial support
Based on the HQ-S scale sum cut-off score (≥ 16), 14% of the sample were identified as in need of psychosocial intervention. When additionally cut-off scores were considered for each individual item, the care need rose to 36%. As can be seen in Table 2 melanoma survivors were primarily burdened by fear of recurrence (M = 1.4) or being anxious (M = 1.2). Fear that people will reject them because of their altered appearance (M = 0.2) or not having confidence in their ability to resume or continue their normal work (M = 0.4) were the lowest burdens.

Table 2. Item and scale analysis of the Hornheide Questionnaire short form (HQ-S).

| Items | % | 0 1 2 3 4 5 | M   | SD | r_\text{it} | n  |
|-------|----|-------------|-----|----|-------------|----|
| 1. I am often anxious. | 42 | 27 14 10 4 3 | 1.2 | 1.35 | .73 | 683 |
| 2. I cannot relax and rest. | 57 | 18 9 8 6 2 | 0.9 | 1.36 | .69 | 680 |
| 3. I am afraid of life with the disease. | 58 | 22 9 5 3 3 | 0.8 | 1.24 | .72 | 677 |
| 4. I do not have confidence in my ability to resume or continue my normal work. | 81 | 9 3 3 1 3 | 0.4 | 1.08 | .52 | 672 |
| 5. I feel physically less productive than prior to falling sick. | 71 | 13 5 4 4 3 | 0.7 | 1.29 | .63 | 679 |
| 6. The thought of the tumour recurring makes me afraid. | 40 | 28 9 9 6 8 | 1.4 | 1.58 | .67 | 683 |
| 7. I fear that people will reject me because of my altered appearance. | 88 | 9 1 1 0 1 | 0.2 | 0.73 | .44 | 680 |
| 8. Talking to my close relatives about my sorrows and fears is difficult. | 68 | 16 6 4 3 3 | 0.7 | 1.25 | .56 | 680 |
| 9. I feel insufficiently informed about my disease and the treatment. | 75 | 11 5 5 3 1 | 0.6 | 1.14 | .51 | 680 |

16-point Likert Scale from 0 = “does not apply” to 5 = “applies and troubles me extremely”, Cronbach’s α = .87; r_\text{it} = discrimination power; item cut-off scores (care need prevalent) underlined
2a care need prevalent, if the sum of the anxiety measuring items (3, 6) is 7, 8, 9 or 10
3Care need index: sum score ≥ 16: 14% of the sample, \( M = 6.78, SD = 7.85 \); need for psychosocial intervention (HQ-S ≥ 16 or underlined item cut-off scores), prevalent 36% (n = 239), not prevalent 64% (n = 433)

doi:10.1371/journal.pone.0132754.t002
We hypothesised that the need for psychosocial care (based on HQ-S scale cut off ≥16 or item cut-off scores) is determined by age, level of school education, fatigue, illness-related social support and time since initial melanoma diagnosis. The results of the multivariate logistic regression are shown in Table 3. “Compared to the youngest group, the need for psychosocial care strongly declined with age” Higher general fatigue (MFI-general), higher symptom burden (EORTC QoL-Symptoms), lower general health (EORTC QoL-General Health), detrimental social interactions (ISSS), a denial/self-blaming coping style (Brief COPE) and high

| Predictor                        | Odds ratio | 95% Confidence Limits | P     |
|----------------------------------|------------|-----------------------|-------|
| Age group < 50                   | 0.54       | 0.32                  | 0.90  | 0.0180 |
| Age 50–69                        | 0.32       | 0.18                  | 0.55  | < .0001 |
| General Fatigue (MFI)            | 1.12       | 1.04                  | 1.20  | 0.0015 |
| Quality of life—Symptoms (EORTC-QoL-C30) | 1.02      | 1.00                  | 1.05  | 0.0259 |
| Quality of life—General Health (EORTC-QoL-C30) | 0.98      | 0.97                  | 1.00  | 0.0087 |
| Detrimental Interactions (ISSS)  | 1.55       | 1.05                  | 2.29  | 0.0258 |
| Denial/Self-blaming (BC)         | 4.57       | 2.38                  | 8.76  | < .0001 |
| Lack of information              | 1.06       | 1.02                  | 1.10  | 0.0041 |

* Multiple Imputation for a set of covariates selected by forward and backward selection (level of selection 5%) in single imputation data

doi:10.1371/journal.pone.0132754.t003

### Predictors of psychosocial care needs

We hypothesised that the need for psychosocial care (based on HQ-S scale cut off ≥16 or item cut-off scores) is determined by age, level of school education, fatigue, illness-related social support and time since initial melanoma diagnosis. The results of the multivariate logistic regression are shown in Table 3. “Compared to the youngest group, the need for psychosocial care strongly declined with age” Higher general fatigue (MFI-general), higher symptom burden (EORTC QoL-Symptoms), lower general health (EORTC QoL-General Health), detrimental social interactions (ISSS), a denial/self-blaming coping style (Brief COPE) and high

### Table 4. Need for psychosocial care (HQ-S) and use of the professional support system (medical, psychosocial), n = 644–659.

| Using Support                      | HQ-S above cut off | χ², p   | Odds Ratio | Confidence Limits |
|------------------------------------|--------------------|---------|------------|-------------------|
| **Dermatological aftercare**       | Yes 236 (36%)  No 423 (64%) |         |            |                   |
| yes                                | 175                | 335     | 510        | 78%              |
| no                                 | 59                 | 84      | 143        | 22%              |
| sum                                | 234                | 419     | 653        | 2.34, ≤ .05      |
| **Psychological counseling**       | yes                | 39      | 8          | 47%              |
| no                                 | 196                | 414     | 610        | 93%              |
| sum                                | 235                | 422     | 657*       | 49.11, ≤ .001    |
| **Psychotherapy (weekly)**         | yes                | 20      | 5          | 25%              |
| no                                 | 217                | 417     | 634        | 96%              |
| sum                                | 237                | 422     | 659*       | 21.88, ≤ .001    |
| **Any psychosocial care**:         | yes                | 59      | 26         | 85%              |
| no                                 | 170                | 389     | 559        | 87%              |
| sum                                | 229                | 415     | 644*       | 48.97, ≤ .001    |
| **Psychopharmacologic drugs**      | yes                | 34      | 12         | 46%              |
| no                                 | 202                | 411     | 613        | 93%              |
| sum                                | 236                | 423     | 659*       | 31.23, ≤ .001    |

*Multiple* Imputation for a set of covariates selected by forward and backward selection (level of selection 5%) in single imputation data

2 x 2 contingency tables, Chi-square tests, odds ratios

*gap to n = 689 due to missing data,

**use of one or more of the following types: psychological counseling, social counseling, pastoral care, self-help group, cancer care counseling, telephone counseling, internet counseling, internet forum (concerned persons)

doi:10.1371/journal.pone.0132754.t004
information needs were significant predictors of being in need for psychosocial intervention. Gender, partnership, anxiety (GAD-7), depression (PHQ-9), fatigue (MFI), a support seeking or active coping style (Brief COPE), positive social support (ISSS), disease stage, time since diagnosis, social class and living in a rural or urban were not significant.

Health care utilisation
As can be seen in Table 4, many of the long-term survivors (22%) reported no medical aftercare consultation, although follow-up visits should be carried out on a yearly basis with this group of patients. Most of them have not used the psychosocial care system or lacked the possibilities to do so: the rate of utilisation does not exceed 7% (n = 47 psychological counselling, n = 46 psychopharmacologic drugs), and even fewer have used psychotherapy (4%, n = 25). Only 13% (n = 46) used one or more kind of professional psychosocial/psycho-oncological help. Survivors in need of professional psychosocial intervention (HQ-S) showed higher probabilities for using the psychosocial support system (odds ratios 5.19–10.30, lowest for any psychosocial support), but a lower probability for getting medical aftercare (odds ratio 0.74).

Conclusions
Given the paucity of data, this study was conducted to (1) identify the psychosocial care needs of long-term survivors of malignant melanoma, (2) the determinants of these psychosocial care needs and then (3) compare expert-defined needs for psychosocial intervention with self-reported utilisation of the health care system.

Prevalence of need for care
The need for psychosocial intervention was based on a standardised measure validated for malignant melanoma, the short form of the Hornheide Questionnaire. After applying the expert-defined threshold, which Strittmatter [24] determined in his standardisation group, we found that 36% of our sample was in need of psychosocial support. This is in concordance with the prevalence data Kasparian et al. [9] found in an international metaanalysis based on studies with recently diagnosed melanoma patients. The prevalence was lower than Strittmatter et al. [41] found with the HQ (45%) in a melanoma sample and much higher than Winzer et al. [11] detected in a small sample, where 9% of outpatients needing professional psychosocial care were found with this instrument. It cannot be precluded that the low cut-off of the HQ-S, which categorises patients as in need when only one item is rated above a certain cut-off, inflates the need prevalence. However, this criterion might be very sensible for the detection of the patient`s burden. Our results indicate that the psychosocial burden (and the care needs) of melanoma patients persists for many years after diagnosis.

Determinants of care needs
As the multivariate approach shows, compared to those without a need, patients who were identified as in need for psychosocial support are characterised by younger age (< 50), higher general fatigue (MFI), higher symptom burden (EORTC), lower general health (EORTC), suffering from detrimental interactions (ISSS), a denial/self-blaming coping style (Brief COPE) and a lack of illness related information; the coping style variable had the highest odds ratio. These findings are in concordance with other psychooncological studies [10, 13, 14, 17, 18, 19, 20]. The above mentioned variables might be used as indicators for offering and referring to psychooncologic support and a trigger for referrals. Unexpectedly, an advanced stage of the disease had no effect on the care needs. Like other objective medical factors [42], it seemed to
have no or little influence on the psychological adjustment of melanoma survivors. The fact that only few of the patients surveyed were in an advanced stage of the disease may have left differences undetected. We had not expected that women have no more need for psychosocial care than men and that neither social class nor education or a steady partnership played a role as this was found in other care need studies, previously [10, 16, 17, 18]. The latter finding may be due to the fact that interactions that can influence care needs are not necessarily caused by the partner but other people around the melanoma patient. Depression and anxiety surprisingly did not determine psychosocial intervention needs. Maybe PHQ und GAD do not capture cancer-related anxiety sufficiently, which might be a reason for being in need for intervention. Besides emotional variables, unfulfilled information needs also were related to the melanoma survivors’ burden. It can be assumed that explanations from the caring physician about illness-related issues are a relatively simple strategy to reduce the burden of the patients. Further studies should direct more attention to this aspect.

Health care system use and subjective care needs

Only 7% of our melanoma sample used psychological counselling, and only 13% reported any type of psychological support. One fifth reported not using dermatological aftercare, which clearly contradicts the guidelines of the German Cancer Society. Patients with a need for psychosocial intervention had a higher probability of using any psychosocial care, especially psychotherapy or psychological counselling. However, overall rates of utilisation were low, confirming the results of a melanoma study where only 15% of patients with a shorter length of illness received psychosocial support [43]. This is very unsatisfactory given that a substantial proportion of these patients were identified as quite burdened. Maybe melanoma survivors in need of psychosocial intervention do not necessarily seek help themselves and remain undetected. Even survivors at high risk of developing new primary disease did not seek formal emotional support to address melanoma-related concerns [44]. As Winzer et al. [11] summarised, there are many barriers for patients that can explain their avoidance of seeking help: not perceiving a need, not knowing that appropriate help is available, not believing that the intervention helps, not finding help accessible, being embarrassed about seeking help or fearing stigmatisation. Additionally, the health care system is often not sensitive or inquisitive enough to detect the patients’ needs [9]. The need for psychosocial intervention may be underestimated by the medical treatment team as psychosocial issues are not communicated between the survivors and the physicians, the referral pathway is unclear, and funding and resources may not be adequate.

Limitations

The strengths of this study reside in the fact that the sample was registry-based. All cancer patients are registered in a central cancer registry by law, insuring its representativeness in the state. However, access to patients is complicated by the fact that the registry is not allowed to contact patients directly, requiring cooperation not only from the former patients but also their physicians many years after the cancer diagnosis and treatment. Unfortunately, many missing data regarding initial tumour stage lead to information gaps in the cancer registry. However, given the course of the disease, we did not expect many survivors from progressive disease after 5 years. While response rates are within range of comparable studies (f. e. [14, 45]), the response rate of 52.2% patients in our study poses a limitation. An additional lies in the use of a broad range of standardised self-report scales, including the measurement for ‘need for psychosocial support’. Care utilisation, however, is also self reported, thereby potentially under or overestimating it. Even though this study focused on long-term survivors, no information was
available about the patients’ distress levels or their care needs at the time of diagnosis and during the melanoma treatment phase. How, why and when the burdens have developed is not known. This might be of interest, because burdens and care needs may change during the trajectory of melanoma aftercare. Longitudinal (intervention-)studies could enlighten the processes of becoming burdened, the rising and fading of care needs and search of professional help to meet them.

Relevance for the health care system

Overall, our results show a strong imbalance between unfulfilled care needs and utilisation of the professional cancer care system. Barriers for obtaining adequate care should be identified, and the aftercare should be adjusted to better support long-term melanoma survivors.

The study underscores the need for regular and systematic screening for psychosocial strains and the need for medical aftercare support after melanoma treatment. In order to fulfil psychosocial care needs for melanoma survivors, it is important to consider their care needs from both the health professionals’ perspective as well as the patients’ perspective themselves. Furthermore, it is of interest to identify extensively burdened risk groups by analysing the determinants of being in need for care.

In order to plan health care services for long-term melanoma survivors, attributes of optimal psychosocial care should be defined. Screening with the HQ-S helps to identify distressed patients and may be a substantial first step towards optimising the use of allocated resources. According to the identified needs, it is essential to provide adequate psycho–oncological support including illness related information (see [46]) in order to foster better health-related quality of life and satisfaction with care. Nevertheless, not all unmet needs for support can be fulfilled; for example professional care cannot fill gaps in the social net of the patients. How to effectively direct patients with meetable needs to available services should also receive more attention.

Acknowledgments

We would like to gratefully acknowledge the continued support of the Deutsche Krebshilfe e. V. (grant number 109225). We greatly appreciate the generous support of the physicians participating (including Berufsverband Dermatologen), and especially the former patients’ willingness to participate. We thank Gerhard Strittmatter for the English version of the HQ-S and Katherine Taylor who assisted with the proof-reading of the manuscript.

Author Contributions

Conceived and designed the experiments: SF BHI MEB MB. Performed the experiments: BHI SF SRZ MB. Analyzed the data: SF VW HB KE SRZ. Wrote the paper: SF MEB SRZ KE PFM.

References

1. RKI, GEKID (2012) Krebs in Deutschland 2009/2010. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.: Berlin.
2. Berking C. (2005) [The role of ultraviolet irradiation in malignant melanoma]. Hautarzt 56: 687–696. PMID: 15968560
3. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ et al. (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118–1125. PMID: 15030614
4. Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A (2008) Treatment of melanoma. Deutsches Arzteblatt international 105: 845–851. doi: 10.3238/arztebl.2008.0845 PMID: 19561811
5. Rychetnik L, McCaffery K, Mortin R, Irwig L (2013) Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psycho-Oncology 22: 721–736. doi: 10.1002/pon.3060 PMID: 22341448

6. Trotter S, Sroa N, Winkelmann RR, Olencki T, Bechtel M (2013) A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol 6: 18–26.

7. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebs- hilfe e.V. (2013) Malignes Melanom S3-Leitlinie „Diagnostik, Therapie und Nachsorge des Mela- nons.“ Kurzversion 1.1—Februar 2013 AWMF-Register-Nummer: 032-024OL. Available: www.awmf. org/uploads/tx_szleitlinien/032-024k_S3_Melanom_Diagnostik_Therapie_Nachtsorge_2013-02.pdf. Accessed 15 March 2014

8. Beutel ME, Blettner M, Fischbeck S, Loquay C, Werner A, Marian H (2009) [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990–2008]. Hautarzt 60: 727–733. doi: 10.1007/s00105-009-1814-1 PMID: 19701615

9. Kasparian N, McLoone J, Butow P (2009) Psychological response and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 145: 1415–1427. doi: 10.1001/archdermatol.2009.308 PMID: 20026852

10. Strittmattre G, Mawrick R, Tilkorn M (1996) [Psychosocial care needs of face and skin tumor patients]. Psychother Psych Med 48: 349–357.

11. Winzer A, Hoppe A, Altenhoff J, Kuwert C, Koch U, Schulz H (2009). Interest in a psycho-educational group intervention among out-patients with malignant melanoma in relation to their need: which patients are likely to participate? Psycho-Oncology 18: 1179–1188. doi: 10.1002/pon.1164 PMID: 19360695

12. Schulz KH, Winzer A, Stump S, Koch U (2001) [Need and usage of psychosocial support after liver transplantation]. Psychother Psych Med 57: 221–230.

13. Blum A, Blum D, Stroebel W, Rassner G, Garbe C, Hautzinger M (2003) [Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up]. Psychother Psych Med 53: 258–266.

14. Mehnert A, Koch U (2008) Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res 64: 383–391. doi: 10.1016/j.jpsychores.2007.12.005 PMID: 18374737

15. Strittmattre G (2004) [Psychosocial counselling of skin cancer patients in times of diagnosis related groups (DRG)]. Hautarzt 55: 735–745. PMID: 15241519

16. Zschocke I (2001) Krankheitsverarbeitung und Gesundheitsverhalten bei Patienten mit Malignem Melanom. Dissertation, Philosophische Fakultät, Albert-Ludwigs-Universität Freiburg i. Br., Germany, 2001. Available: http://www.freidok.uni-freiburg.de/volltexte/323. Accessed 20 March 2014.

17. Herschbach P (2006) [The need for treatment in psychooncology. Principles and assessment strategies]. Onkologe 12: 41–47.

18. Hamama-Raz Y (2012) Does psychological adjustment of melanoma sufferers differ between genders? Psycho-Oncology 21: 255–263. doi: 10.1002/pon.1889 PMID: 22383267

19. Söllner W, Mairinger G, Zingg-Schirr M, Fritsch P (1996) [Cancer prognosis, psychosocial stress and attitude of melanoma patients to supportive psychotherapy]. Hautarzt 47: 200–205. PMID: 8647703

20. Söllner W, Zingg-Schirr M, Rumpold G, Mairinger C, Fritsch P (1998) [Need for supportive counselling – the professionals’ versus the patients’ perspective: a survey in a representative sample of 236 melanoma patients]. Psychother Psychosom 67: 94–104 PMID: 9556201

21. Sigurdardottir V, Bolund S, Sullivan M (1996) Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncologica 35: 149–158. PMID: 8639309

22. Loquai C, Scheurich V, Syring N, Schmidtmann I, Müller-Brenne T, Werner A et al. (2014). Characterizing psychosocial distress in melanoma patients using the expert rating instrument PO-Baso SF. JEADV, 28, 1676–1684. doi: 10.1111/jdv.12361 PMID: 24484382

23. Loquai C, Scheurich V, Syring N, Schmidtmann I, Rietz S, Werner A et al. (2013) Screening for distress in routine oncological care—A survey in 520 melanoma patients. PLOS ONE doi: 10.1371/journal. pone.0066800

24. Strittmattre G (1997). Indikation zur Intervention in der Psychoonkologie: psychosoziale Belastungen und Ermittlung der Betreuungsbedürftigkeit stationärer Hauttumorpatienten. Waxmann: Münster.

25. Strittmattre G (2003) HF. Homheider Fragebogen. In: Schumacher J, Klaiber A, Brähler E, editors. Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Hogrefe: Göttingen. pp. 164–169.

26. Vodermaier A, Linden W, Siu W (2009) Screening for emotional distress in cancer patients: A systematic review of assessment instruments. J Natl Cancer Inst 101:1464–1488.
27. Bermejo I, Niebling W, Berger M, Härter M (2005). Patients' and physicians' evaluation of the PHQ-D for depression screening. Primary Care and Community Psychiatry 10: 125–131.
28. Loewe B, Müller S, Brähler E, Kroenke K, Albani C, Decker O (2007) [Validation and standardization of a brief measure for assessing generalized anxiety disorder (GAD-7) in a representative sample of the German general population]. Psychother Psych Med 57: A050.
29. Gilbody S, Richards D, Brealey S, Hewitt C (2007) Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 22: 1596–1602. PMID: 17874169
30. Loewe B, Grafe K, Zipfel S, Witte S, Loerch B, Herzog W (2004) Diagnosing ICD-10 depressive episodes: superior criterion validity of the Patient Health Questionnaire. Psychother Psychosom 73: 386–390. PMID:15479995
31. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376. PMID: 843390
32. Smets EM, Garssen B, Bonke B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39: 315–325. PMID: 7636775
33. Schwarz R, Krauss O, Hinz A (2003). [Fatigue in the General Population]. Onkologie 26: 140–144. PMID: 12771522
34. Ramm GC, Hasenbring M (2003). [The German adaptation of the Illness-specific Social Support Scale and its statistical evaluation at an application before and after bone marrow transplantation]. Z Med Psychol 12: 29–38.
35. Carver CS (1997) You want to measure coping but your protocol's too long: Consider the Brief COPE. Int J Behav Med 4: 92–100. PMID: 16250744
36. Carver CS, Scheier MF, Weintraub JK (1989) Assessing coping strategies: A theoretically based approach. J Pers Soc Psychol 56: 267–283. PMID: 2926629
37. Knoll N (2002). Coping as a Personality Process: How elderly patients deal with cataract surgery. Dissertation. University of Berlin, 2002. Available: http://www.diss.fu-berlin.de/2002/108/ Accessed 4 February 2013
38. Krägeloh CU (2011) A systematic review of studies using the Brief COPE: Religious coping in factor analyses. Religion 2, 216–246.
39. Lampert T, Kroll LE (2009) Die Messung des soziökonomischen Status in sozialepidemiologischen Studien. In: Richter M, Hurrelmann K (eds.), Gesundheitliche Ungleichheit. Grundlagen, Probleme, Perspektiven, 2. aktualisierte Auflage. Wiesbaden: VS Verlag für Sozialwissenschaften, pp. 309–334.
40. Molenberghs G, Kenward MG (2007) Missing Data in Clinical Studies. Chichester: John Wiley & Sons Ltd.
41. Strittmatter G, Mawick R, Tilkorn M (1998) Psychosozialer Betreuungsbedarf bei Gesichts- und Hauttumorpatienten. Psychother Psychosom Med Psychol 48: 349–357
42. Hamama-Raz Y, Solomon Z, Schachter J, Azizi E (2007) Objective and subjective stressors and the psychological adjustment of melanoma survivors. Psycho-Oncology 16: 287–294. PMID: 18858669
43. Nashan D, Kirschner F, Strittmatter G, Hirche H, Loquai C et al. (2004) [Patients’ view of melanoma follow-up.]. JDDG 2: 105–110. PMID: 16279244
44. McLoone J, Watts K, Menzies S, Meiser B, Butow P, Kasparian N (2012) When the risks are high: Psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qual Health Res 22: 1102–1113. doi: 10.1177/1049732312448542 PMID: 22673092
45. Waldmann A, Nolte S, Pritzkuleit R, Breitbart EW, Katalinic A (2011) Different aspects of self-reported quality of life in 450 German melanoma survivors. Cancer 3: 2316–2332.
46. Husson O, Mols F, Oranje WA, Haak HR, Nieuwlaat WA, Netea-Maier RT et al. (2014) Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: results of the PROFILES registry. Psycho-Oncology 2014, doi: 10.1002/pon.3514